GSK Stock: Earnings Outlook Upgrade, Attractive Valuations (OTCMKTS:GLAXF)

GlaxoSmithKline in Dresden


Since the last time I wrote about the British bio-pharma company GSK plc (NYSE:GSK) in January of this year, its price has barely moved. It has softened by under 2%. It’s year-to-date [YTD] performance is similarly underwhelming, with a 1.3% rise. This lack of

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *